×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RLMD – relmada therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
03:17 pm
rlmd
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See [Seeking Alpha]
Low
Report
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See [Seeking Alpha]
3/30
03:10 am
rlmd
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director [Yahoo! Finance]
Low
Report
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director [Yahoo! Finance]
3/25
01:44 am
rlmd
Here's What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock [Yahoo! Finance]
Medium
Report
Here's What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock [Yahoo! Finance]
3/24
09:00 am
rlmd
Relmada Therapeutics (RLMD) is now covered by Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.
Low
Report
Relmada Therapeutics (RLMD) is now covered by Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.
3/20
10:28 am
rlmd
Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.
Low
Report
Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.
3/19
11:02 pm
rlmd
Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]
Low
Report
Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]
3/19
07:51 pm
rlmd
Relmada (RLMD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Relmada (RLMD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/19
06:03 pm
rlmd
Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
3/19/2026
04:01 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-2.9%
relmada therapeutics, inc.
11/13/2025
04:01 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-0.5%
relmada therapeutics, inc.
8/7/2025
04:05 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-2.4%
relmada therapeutics, inc.
5/12/2025
04:01 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-2.1%
relmada therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:53 pm
rlmd
Form 8-K RELMADA THERAPEUTICS, For: Mar 19
Low
Report
Form 8-K RELMADA THERAPEUTICS, For: Mar 19
3/19
04:26 pm
rlmd
Form 10-K RELMADA THERAPEUTICS, For: Dec 31
Medium
Report
Form 10-K RELMADA THERAPEUTICS, For: Dec 31
3/9
07:11 am
rlmd
Form 8-K RELMADA THERAPEUTICS, For: Mar 09
High
Report
Form 8-K RELMADA THERAPEUTICS, For: Mar 09
2/17
12:19 pm
rlmd
Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
Medium
Report
Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
2/17
09:15 am
rlmd
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Spruce Street Capital LP
Medium
Report
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Spruce Street Capital LP
2/12
09:13 am
rlmd
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Adage Capital Management, L.P.
Low
Report
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Adage Capital Management, L.P.
2/6
04:32 pm
rlmd
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: JANUS HENDERSON GROUP PLC
1/30
05:14 pm
rlmd
Form 424B5 RELMADA THERAPEUTICS,
Medium
Report
Form 424B5 RELMADA THERAPEUTICS,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
TOP News Decliners
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: